<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Exenatide once weekly is the first <z:chebi fb="105" ids="17234">glucose</z:chebi>-lowering agent available to patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (T2DM) which is administered once per week </plain></SENT>
<SENT sid="1" pm="."><plain>This long-acting formulation contains the same active ingredient as exenatide twice daily, except that the exenatide is encapsulated in dissolvable microspheres </plain></SENT>
<SENT sid="2" pm="."><plain>Following subcutaneous injection, exenatide once weekly microspheres remain in place under the skin and slowly degrade, releasing active exenatide continuously into circulation </plain></SENT>
<SENT sid="3" pm="."><plain>In randomized clinical trials, exenatide once weekly was associated with significant glycaemic improvement and moderate <z:hpo ids='HP_0001824'>weight loss</z:hpo> in patients with T2DM when administered as monotherapy or in combination with a variety of oral <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> agents </plain></SENT>
<SENT sid="4" pm="."><plain>Exenatide once weekly also lowered blood <z:chebi fb="105" ids="17234">glucose</z:chebi> more effectively than titrated basal insulin in patients on <z:chebi fb="0" ids="6801">metformin</z:chebi> or <z:chebi fb="0" ids="6801">metformin</z:chebi> plus sulphonylurea background therapy </plain></SENT>
<SENT sid="5" pm="."><plain>Gastrointestinal side effects (<z:hpo ids='HP_0002018'>nausea</z:hpo>, <z:hpo ids='HP_0002013'>vomiting</z:hpo> and diarrhoea) were the most common tolerability issues associated with exenatide once weekly administration, but they occurred at lower rates than in patients on other glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi> receptor <z:chebi fb="4" ids="48705">agonists</z:chebi> (i.e., exenatide twice daily or liraglutide) </plain></SENT>
<SENT sid="6" pm="."><plain>Issues regarding the place of exenatide once weekly in T2DM pharmacotherapy are discussed </plain></SENT>
</text></document>